1. Home
  2. LOAN vs STTK Comparison

LOAN vs STTK Comparison

Compare LOAN & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOAN
  • STTK
  • Stock Information
  • Founded
  • LOAN 1989
  • STTK 2016
  • Country
  • LOAN United States
  • STTK United States
  • Employees
  • LOAN N/A
  • STTK N/A
  • Industry
  • LOAN Real Estate Investment Trusts
  • STTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOAN Real Estate
  • STTK Health Care
  • Exchange
  • LOAN Nasdaq
  • STTK Nasdaq
  • Market Cap
  • LOAN 65.8M
  • STTK 56.8M
  • IPO Year
  • LOAN 1999
  • STTK 2020
  • Fundamental
  • Price
  • LOAN $5.75
  • STTK $1.37
  • Analyst Decision
  • LOAN
  • STTK Hold
  • Analyst Count
  • LOAN 0
  • STTK 3
  • Target Price
  • LOAN N/A
  • STTK $2.00
  • AVG Volume (30 Days)
  • LOAN 10.2K
  • STTK 131.9K
  • Earning Date
  • LOAN 03-10-2025
  • STTK 03-03-2025
  • Dividend Yield
  • LOAN 8.00%
  • STTK N/A
  • EPS Growth
  • LOAN 6.53
  • STTK N/A
  • EPS
  • LOAN 0.49
  • STTK N/A
  • Revenue
  • LOAN $7,394,068.00
  • STTK $6,435,000.00
  • Revenue This Year
  • LOAN N/A
  • STTK $313.04
  • Revenue Next Year
  • LOAN N/A
  • STTK N/A
  • P/E Ratio
  • LOAN $11.73
  • STTK N/A
  • Revenue Growth
  • LOAN 5.79
  • STTK 382.75
  • 52 Week Low
  • LOAN $4.60
  • STTK $0.94
  • 52 Week High
  • LOAN $5.90
  • STTK $11.76
  • Technical
  • Relative Strength Index (RSI)
  • LOAN 59.17
  • STTK 60.23
  • Support Level
  • LOAN $5.55
  • STTK $1.21
  • Resistance Level
  • LOAN $5.82
  • STTK $1.36
  • Average True Range (ATR)
  • LOAN 0.09
  • STTK 0.10
  • MACD
  • LOAN 0.00
  • STTK 0.01
  • Stochastic Oscillator
  • LOAN 79.41
  • STTK 90.00

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Share on Social Networks: